Marty 2005.

Methods	Randomized, single dose, double‐blind, active‐controlled parallel‐group Medication administered when baseline pain reached moderate‐to‐severe intensity
Participants	Type of surgery: gynecological Paracetamol group Entered/completing: 80/80 Age (mean, SD): 38.3 ± 12.8 Sex (male, %): 0 Propacetamol group Entered/completing: 81/81 Age (mean, SD): 33.9 ± 12.0 Sex (male, %): 0
Interventions	Intervention: paracetamol 1g IV in 100 ml solution over 15 min Active control: propacetamol 2 g in 100 ml solution
Outcomes	Primary outcome: tolerability, including pain at infusion site Pain intensity (VRS, VAS) Number of participants requesting rescue medication Patient satisfaction (categorical)
Source of funding	Not mentioned, but senior author was employee of Bristol Myers Squibb
Were treatment groups comparable at baseline?	Yes: weight, type of surgery, baseline pain intensity at surgical site. No ‐ age: 38.3 paracetamol versus 33.9 propacetamol.
Details of preoperative pain	Patients with any painful physical condition (other than postoperative pain) were excluded.
Notes	—
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Participants were randomly assigned in a 1:1 ratio according to a computer‐generated list of numbers to either group
Allocation concealment (selection bias)	Unclear risk	Not described
Blinding (performance bias and detection bias) All outcomes	Low risk	Study drugs mixed by pharmacist or nurse not involved in the study, were administered as a 100 ml solution infused over 15 min
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	"A total of 163 women were enrolled and 161 received the single infusion of study medication. All remaining 161 patients including 2 patients (1 in each group) who did not meet eligibility criteria, were included in the ITT population and analyses of demographic characteristics, tolerability, and efficacy". Not clear if data were imputed.
Selective reporting (reporting bias)	Low risk	Free of selective reporting. All outcomes from Methods section reported in Results section.
Size	Unclear risk	50 to 199 participants per arm of the study (80 paracetamol, 81 propacetamol)